an innovative operational model can work perfectly well in combination with "niche" areas like the development of orphan & rare disease drugs
Milton Keynes, UK (PRWEB) August 26, 2012
The company's CEO, Thomas Ogorka, summarised QED's strategy moving forward: "We can clearly see a strong industry trend for orphan drug development activities. Any company developing drugs for orphan indications needs a service provider who can not only offer tailor-made solutions in a very effective and attentive way, but also has access to these rare patient populations no matter where in the world. QED's new "OrphanReach" division offers our sponsors exactly that: a lean management structure with excellent client attention and at the same time the global reach element which one would have thought only the largest CROs can provide. QED is a good example that an innovative operational model can work perfectly well in combination with "niche" areas like the development of orphan & rare disease drugs thus providing sponsors with a powerful CRO alternative."
Orphan drug development is one of the fastest growing areas in clinical research, and also one of the most challenging. OrphanReach capitalises on QED’s global infrastructure, yet employs a flexible, adaptive approach, providing an excellent fit with orphan drug development needs. It is through the experience of the QED team of specialist research professionals, based in the UK head office, within rare indication trials that OrphanReach can command confidence that trials will yield high quality data thus increasing the confidence of the Regulatory Authorities when reviewing the Clinical Trial Application. Furthermore, trials are led by strong project management teams, who understand the importance of critical milestones being met on time and on budget.